Takatsuki Shinichi, Wagner Brandie D, Ivy David Dunbar
Department of Pediatrics, University of Colorado Denver School of Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA.
Congenit Heart Dis. 2012 May-Jun;7(3):259-67. doi: 10.1111/j.1747-0803.2011.00620.x. Epub 2012 Feb 10.
B-type natriuretic peptide (BNP) and the amino-terminal fragment (NTproBNP) correlate with clinical variables, but have not been simultaneously studied in a large number of pediatric patients with pulmonary arterial hypertension (PAH). The purpose of our investigation was to compare BNP and NTproBNP with clinical indicators of disease in a pediatric PAH population for which biomarkers are much needed.
We retrospectively compared BNP and NTproBNP levels with exercise capacity, echocardiographic data, and hemodynamics in PAH patients under 21 years old. Two hundred sixty-three blood samples from 88 pediatric PAH patients were obtained, with BNP and NTproBNP drawn at the same time.
There was a correlation between BNP and NTproBNP with mean pulmonary arterial pressure/mean systemic arterial pressure ratio (r= 0.40, P < .01; r= 0.45, P < .01; respectively), mean right atrial pressure (r= 0.48, P < .01; r= 0.48, P < .01), and tricuspid regurgitant velocity (r= 0.36, P < .01; r= 0.41, P < .01). BNP and NTproBNP are associated with 6-minute walk distance, mean pulmonary arterial pressure, mean pulmonary arterial pressure/mean systemic arterial pressure ratio, mean right atrial pressure, pulmonary vascular resistance index, and tricuspid regurgitant velocity when investigated longitudinally. On the average, a 1-unit increase in log BNP or NTproBNP was associated with 4.5 units × m(2) or 3.4 units × m(2) increase in pulmonary vascular resistance index, respectively. There was a strong correlation between log BNP and log NTproBNP measurements (r= 0.87, P < .01).
In pediatric PAH, BNP and NTProBNP are strongly correlated and predict changes in clinical variables and hemodynamics. In a cross-sectional analysis, NTproBNP correlated with echocardiographic and exercise data better than BNP; NTproBNP showed less within patient variability over time; therefore, NTproBNP can add additional information toward predicting these clinical measurements.
B型利钠肽(BNP)和氨基末端片段(NTproBNP)与临床变量相关,但尚未在大量小儿肺动脉高压(PAH)患者中同时进行研究。我们研究的目的是在急需生物标志物的小儿PAH人群中,比较BNP和NTproBNP与疾病临床指标的关系。
我们回顾性比较了21岁以下PAH患者的BNP和NTproBNP水平与运动能力、超声心动图数据及血流动力学。从88例小儿PAH患者中获取了263份血样,同时检测BNP和NTproBNP。
BNP和NTproBNP与平均肺动脉压/平均体动脉压比值(分别为r = 0.40,P <.01;r = 0.45,P <.01)、平均右房压(r = 0.48,P <.01;r = 0.48,P <.01)及三尖瓣反流速度(r = 0.36,P <.01;r = 0.41,P <.01)之间存在相关性。纵向研究时,BNP和NTproBNP与6分钟步行距离、平均肺动脉压、平均肺动脉压/平均体动脉压比值、平均右房压、肺血管阻力指数及三尖瓣反流速度相关。平均而言,log BNP或NTproBNP每增加1个单位,分别与肺血管阻力指数增加4.5单位×m²或3.4单位×m²相关。log BNP与log NTproBNP测量值之间存在强相关性(r = 0.87,P <.01)。
在小儿PAH中,BNP和NTProBNP密切相关,并可预测临床变量和血流动力学变化。在横断面分析中,NTproBNP与超声心动图和运动数据的相关性优于BNP;NTproBNP随时间的患者内变异性较小;因此,NTproBNP可为预测这些临床测量提供额外信息。